Guardant Health, Inc. announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego. Multiple poster sessions will report on the utility of using the Guardant Infinity?? platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction.

Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen. The Guardant Infinity smart liquid biopsy platform used in many of the studies combines genomic and epigenomic profiling to deliver multidimensional insights that allow researchers and clinicians to characterize and quantify cancer--in areas such as tumor heterogeneity, disease progression and treatment response. The epigenomic insights enable more personalized treatment strategies by increasing accuracy in minimal residual disease detection and monitoring through enhanced ctDNA detection and quantification, and by identifying new patients or predicting response to therapy through novel epigenomic biomarkers.